Adastra Holdings Ltd. (XTXXF) stock
Close on Oct 19, 2026
Adastra Holdings Ltd. grew revenue 136.2% to C$13.30M over fiscal 2022. Free cash flow was C$694.07K.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2022, balances at Dec 31, 2022
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- C$13.30M
- EPS, diluted
- -0.07 CAD
- Free cash flow
- C$694.07K
Trading
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 0
Valuation needs the share price. It fills in once daily prices are connected and converted from CAD.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | XTXXF | S&P 500 | Difference | XTXXF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | 0.0% | +3.4% | −3.4 pts | ||
| Year to date | -30.0% | +13.3% | −43.3 pts | ||
| 1 year | -98.6% | +16.6% | −115.2 pts | ||
| 3 years | -99.4% | +86.4% | −185.8 pts | -81.6% | +23.1% |
| 5 years | -99.9% | +81.9% | −181.8 pts | -76.2% | +12.7% |
Three years at a glance
Fiscal years 2020 to 2022, CAD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Adastra filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Adastra
Pharmaceutical Preparations
Adastra Holdings Ltd. is an extraction and processing solutions company operating in the Canadian cannabis sector. It develops and utilizes extraction technologies, including supercritical carbon dioxide, cryogenic ethanol, and hydrocarbon systems, to process cannabis and hemp biomass into bulk distillates, oils, hydrocarbon extracts, shatter, and vaporizing products. Through its Chemia Analytics subsidiary, the company conducts analytical and organoleptic testing services, covering potency, microbial contamination, and formulation consulting. Its PerceiveMD clinic operations involve healthcare professionals providing medical cannabis consultations and therapies. Adastra serves licensed cannabis standard cultivators, micro-cultivators, processors, provincial distributors, and medical patients.
Company profile, executives and historyAdastra stock: common questions
What is Adastra's stock price?
XTXXF closed at $0.01 on Oct 19, 2026, up 0.00% on the day.
What is XTXXF's P/E ratio?
Adastra lost money over fiscal 2022 (diluted EPS -0.07 CAD), so it has no meaningful P/E ratio.
How much revenue does Adastra make?
Adastra reported revenue of C$13.30M for fiscal 2022, up 136.2% from a year earlier.
Does Adastra pay a dividend?
No. Adastra has not paid a cash dividend over the last twelve months.
How has XTXXF stock performed over the past year?
Including dividends, XTXXF returned -98.6% over the past year, against +16.6% for the S&P 500.
Who are Adastra's competitors?
Companies most similar to Adastra by business, industry and size include OGI, CPMD, INCR, BHST, VREOF.
See a number that looks wrong?